A randomized phase II trial showed significant benefit for gemcitabine , carboplatin , and iniparib ( GCI ) over gemcitabine and carboplatin ( GC ) in clinical benefit rate , response rate , progression-free survival ( PFS ) , and overall survival ( OS ) .